Oct. 19, 2023 (GLOBE NEWSWIRE) -- NKGen Biotech Inc. (Nasdaq ... today announced an upcoming poster presentation on a final report of a Phase I dose escalation study of SNK01 in subjects with ...

The poster will be available on ... are based on IO Biotech’s current assumptions and expectations of future events and trends, which affect or may affect its business, strategy, operations ...

IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune modulating cancer vaccines based on its T-win ® technology platform, today announced three poster ...

MAIA Biotechnology, Inc., (NYSE American ... a potential predictive biomarker for THIO treatment was selected for poster presentation at the European Lung Cancer Congress 2025 (ELCC 2025) taking ...

The forums — which typically include talks, poster presentations ... Plenty of other regular biotech social gatherings exist, including networking event Biotech Tuesday and a biotech softball ...

The event is taking place on Prague, Czech Republic, from 20 to 22 March 2017 and PCI Biotech will present a poster on 21 March, 17:30 local time (CET). The poster will be presented by Dr. Tone ...

If anyone has information on the whereabouts of the TAK-279 poster, Fierce Biotech is standing by to collect tips. We intend to work tirelessly—at least until the next news cycle, anyway—to ...

where the event will take place, sits on acreage directly behind the company's original building, located in the research park at 1425 Innovation Place in West Lafayette. The ceremony is not open to ...

Dhanashree Mhatre, a PhD student at Punjab Agricultural University (PAU), has been conferred with the best poster award during ... This biennial event was... The Tribune, now published from ...

Oct. 08, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech Inc. (Nasdaq ... today announced upcoming poster presentations on a final report of a Phase 1 dose escalation study and on a preliminary report ...

The clinical trial is sponsored by IO Biotech and conducted in collaboration with Merck. IO Biotech maintains global commercial rights to IO102-IO103. About IOB-032/PN-E40 Phase 2 Basket Trial in ...